Related Experiment Video

Updated: Aug 15, 2026

Grafting of Beads into Developing Chicken Embryo Limbs to Identify Signal Transduction Pathways Affecting Gene Expression
11:48

Grafting of Beads into Developing Chicken Embryo Limbs to Identify Signal Transduction Pathways Affecting Gene Expression

Published on: January 17, 2016

Should recombinant human growth hormone therapy be used in short small for gestational age children?

L B Johnston1, M O Savage

  • 1Paediatric Endocrine Section, Department of Endocrinology, William Harvey Research Institute, Barts and the London Queen Mary School of Medicine, London, UK. l.b.Johnston@qmul.ac.uk

Archives of Disease in Childhood
|July 23, 2004
PubMed

Insights

Short small for gestational age (SGA) children often have short stature. Recombinant human growth hormone (GH) is now approved for treating these children, offering a new therapeutic option.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Growth Disorders

Background:

  • Short small for gestational age (SGA) children comprise 20% of pediatric short stature cases.
  • SGA short stature presents a significant clinical challenge in growth clinics.
  • Limited therapeutic options historically existed for SGA short stature.

Purpose of the Study:

  • To examine the role of recombinant human growth hormone (GH) therapy in children born small for gestational age (SGA) who exhibit short stature.
  • To review patient selection criteria for GH therapy in this population.
  • To assess the effectiveness, safety, and metabolic implications of GH treatment in short SGA children.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Analysis of data regarding GH therapy outcomes in SGA children.
  • Evaluation of safety profiles and potential metabolic side effects.

Main Results:

  • Recombinant human growth hormone (GH) is now a licensed treatment for short stature in SGA children in the European Union.
  • GH therapy has demonstrated effectiveness in improving growth in short SGA children.
  • Safety and metabolic profiles require careful monitoring during treatment.

Conclusions:

  • GH therapy represents a significant advancement for managing short stature in SGA children.
  • Careful patient selection and monitoring are crucial for optimizing outcomes and safety.
  • Further research into long-term metabolic effects is warranted.

More Related Videos

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Related Concept Videos

Recombinant DNA01:09

Recombinant DNA

Overview
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...